Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BreathRx Antibacterial Spray is an over-the-counter oral care product developed by Philips (under the Sonicare brand) for the treatment and prevention of halitosis (oral malodor). The formulation features 0.075% cetylpyridinium chloride (CPC), a quaternary ammonium antiseptic that acts by disrupting the cell membranes of gram-negative anaerobic bacteria responsible for producing volatile sulfur compounds (VSCs). Additionally, the spray incorporates ZYTEX, a proprietary blend of zinc gluconate, eucalyptus oil, and thymol, which works to neutralize existing VSCs. The product is 100% alcohol-free and is designed for topical oral use, often in combination with mechanical tongue cleaning systems like the Sonicare TongueCare+.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on BreathRx antibacterial spray.